Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
Ira Winer, MD, PhD, FACOG
Advertisement
Articles by Ira Winer, MD, PhD, FACOG
Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.
Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.
Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.
Advertisement
Latest Updated Articles
Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022Published: March 29th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
4
Examining the Full Scope of Future Advancements in Radiation Oncology
5
